A slight trend toward decreased response with lower doses was observed at doses <1.0 × 10 8 cells; however, because of the small number of nonresponders, these findings should be interpreted with caution.
← all excerpts
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
1
—
—